September 19, 2018 08:03 AM EDT

Silverback starts to slowly edge out of stealth mode — but there’s still plenty being kept under wraps

John Carroll

Editor & Founder

Silverback Therapeutics was one of those stealthy biotechs that some tech writers loved to try and track. The company surfaced when backers recruited a high …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Silverback starts to slowly edge out of stealth mode — but there’s still plenty being kept under wraps

John Carroll

Editor & Founder

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Applied Therapeutics' rare disease drug gets a CRL

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Sil­ver­back starts to slow­ly edge out of stealth mode — but there’s still plen­ty be­ing kept un­der wraps

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Silverback starts to slowly edge out of stealth mode — but there’s still plenty being kept under wraps

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Applied Therapeutics' rare disease drug gets a CRL

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya